Eton Pharmaceuticals to Report Third Quarter Financial Results on Thursday, November 12, 2020
Eton Pharmaceuticals (ETON) announced it will release its third quarter 2020 financial and operational results on November 12, 2020. A conference call to discuss these results and provide a business update is scheduled for 4:30 p.m. ET. The call can be accessed domestically at 1-866-795-8473 and internationally at 1-470-495-9161. Eton specializes in innovative treatments for rare pediatric diseases and has three FDA-approved products, with six additional products in late-stage development, five of which are submitted to the FDA.
- Three FDA-approved products currently available: ALKINDI® SPRINKLE, Biorphen®, and Alaway® Preservative Free.
- Six additional products in late-stage pipeline, with five submitted to the FDA.
- None.
DEER PARK, Ill., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it will report third quarter 2020 financial and operating results on Thursday, November 12, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (3:30 p.m. CT).
The live webcast can be accessed on the investors section of Eton’s website at https://ir.etonpharma.com/. The conference call can be accessed by dialing 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 5092872. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases. The company currently owns or receives royalties from three FDA-approved approved products, including ALKINDI® SPRINKLE, Biorphen®, and Alaway® Preservative Free, and has six additional products in its late-stage pipeline, including five that have been submitted to the FDA.
Investor Contact:
David Krempa
dkrempa@etonpharma.com
612-387-3740
FAQ
When will Eton Pharmaceuticals report third quarter 2020 results?
What time is the Eton Pharmaceuticals conference call?
How can I access Eton Pharmaceuticals' live conference call?
What products does Eton Pharmaceuticals currently have approved by the FDA?